Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Evaluation of the Efficacy and Safety of High-Flow Oxygen Therapy Compared With a Nasal Positive Airway Pressure (nPAP) Mask Using Transcutaneous Capnometry During Endoscopic Procedures in High-Risk Patients (HiPERion)

6 november 2026 uppdaterad av: Thomas Seufferlein, University of Ulm

The HiPERion Trial is a prospective, randomized, controlled, non-inferiority study designed to compare the efficacy and safety of two oxygen and respiratory support methods during sedated endoscopic procedures in patients at increased risk of respiratory complications.

Patients with significant pre-existing medical conditions (American Society of Anesthesiologists [ASA] physical status III or IV) have an increased risk of breathing-related complications during endoscopic procedures performed under sedation. These complications include low blood oxygen levels (hypoxemia) and elevated carbon dioxide levels in the blood (hypercapnia).

The study will compare two respiratory support methods: high-flow nasal cannula (HFNC) oxygen therapy and a nasal positive airway pressure (nPAP) system using the SuperNO2VA mask. Both methods are used to support breathing and maintain adequate oxygen levels during medical procedures. However, they differ in their technical approach and in the way they support ventilation.

A total of 140 adult patients undergoing diagnostic or therapeutic endoscopic procedures lasting more than 15 minutes will be enrolled at the University Hospital Ulm, Germany. Eligible participants will be randomly assigned to receive either HFNC oxygen therapy or respiratory support via the nPAP mask during the procedure.

Throughout the endoscopic procedure, patients will receive standard clinical monitoring, including measurement of oxygen saturation, heart rate, and blood pressure. In addition, carbon dioxide levels will be continuously monitored using a non-invasive transcutaneous capnometry sensor attached to the patient's forehead. This method allows continuous measurement of carbon dioxide levels through the skin without the need for additional blood sampling.

The primary objective is to compare the occurrence of hypoxemic events between the two respiratory support methods. Hypoxemia is defined as a decrease in oxygen saturation below 90% lasting more than 10 seconds. Severe hypoxemic events, defined as a decrease in oxygen saturation below 80% lasting more than 10 seconds, will also be assessed.

Secondary objectives include comparing changes in transcutaneous carbon dioxide levels during the procedure, the number of interventions required to maintain an open airway or optimize respiratory support, and the occurrence of adverse events.

The study aims to determine whether respiratory support using the nPAP mask is not inferior to HFNC oxygen therapy in terms of safety and prevention of hypoxemic events during endoscopic procedures in high-risk patients. The findings may help identify an effective and safe respiratory support strategy for this patient population.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

140

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Ulm, Tyskland, 89081
        • University Hospital Ulm

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Adults aged 18 years or older.
  • American Society of Anesthesiologists (ASA) physical status III or IV.
  • Patients undergoing diagnostic or therapeutic endoscopic procedures with an expected duration of more than 15 minutes.
  • Written informed consent to participate in the study.

Exclusion Criteria:

  • Patients unable or unwilling to provide informed consent.
  • Known pregnancy.
  • Intolerance or contraindications to sedation.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: HFNC Group

High-Flow Nasal Cannula (HFNC) Oxygen Therapy

Patients assigned to the HFNC group will receive high-flow nasal cannula oxygen therapy during the endoscopic procedure. The oxygen flow rate will be set at 40 L/min with an inspired oxygen concentration (FiO₂) of 40%. Transcutaneous carbon dioxide levels will be continuously monitored using a non-invasive forehead sensor. Standard monitoring of peripheral oxygen saturation (SpO₂), heart rate, and blood pressure will be performed throughout the procedure.

Aktiv komparator: nPAP Group

Nasal Positive Airway Pressure (nPAP) Using the SuperNO2VA Mask

Patients assigned to the nPAP group will receive respiratory support using a nasal positive airway pressure (nPAP) system with the SuperNO2VA nasal mask throughout the endoscopic procedure. Transcutaneous carbon dioxide levels will be continuously monitored using a non-invasive forehead sensor. Standard monitoring of peripheral oxygen saturation (SpO₂), heart rate, and blood pressure will be performed throughout the procedure.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of Hypoxemic Events
Tidsram: During the endoscopic procedure.

Number of hypoxemic events, defined as a peripheral oxygen saturation (SpO₂) below 90% lasting more than 10 seconds, during the endoscopic procedure.

During the endoscopic procedure.
Number of Severe Hypoxemic Events
Tidsram: During the endoscopic procedure.

Number of severe hypoxemic events, defined as a peripheral oxygen saturation (SpO₂) below 80% lasting more than 10 seconds, during the endoscopic procedur

During the endoscopic procedure.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Transcutaneous Carbon Dioxide Levels (tcPCO₂)
Tidsram: During the endoscopic procedure.

Difference between the initial transcutaneous carbon dioxide level (tcPCO₂) and the mean tcPCO₂ level measured during the endoscopic procedure. Continuous non-invasive monitoring will be performed using a transcutaneous forehead sensor.

During the endoscopic procedure.
Number of Airway Support Interventions
Tidsram: During the endoscopic procedure.

Number of airway support interventions required during the endoscopic procedure, including head repositioning and repositioning or adjustment of the nPAP mask or HFNC nasal cannula.

During the endoscopic procedure.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

13 oktober 2026

Primärt slutförande (Beräknad)

13 mars 2027

Avslutad studie (Beräknad)

13 juni 2027

Studieregistreringsdatum

Först inskickad

6 november 2026

Först inskickad som uppfyllde QC-kriterierna

6 november 2026

Första postat (Faktisk)

12 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 20/25 FSt/Sta Ulm

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera